AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of AbbVie Inc. (NYSE:ABBV) have been given a consensus recommendation of “Moderate Buy” by the twenty-seven research firms that are currently covering the company, Marketbeat Ratings reports. Ten analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $240.1429.

ABBV has been the subject of a number of recent research reports. JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Raymond James Financial set a $256.00 target price on AbbVie in a research report on Monday, November 3rd. UBS Group upped their price target on AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a report on Friday, November 7th. BMO Capital Markets raised their price objective on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. Finally, Hsbc Global Res downgraded shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 1st.

Institutional Trading of AbbVie

A number of hedge funds and other institutional investors have recently made changes to their positions in ABBV. TD Capital Management LLC raised its position in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after purchasing an additional 58 shares during the last quarter. Marshall & Sullivan Inc. WA acquired a new position in AbbVie in the second quarter valued at $25,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the third quarter valued at $31,000. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie in the second quarter valued at about $26,000. Finally, Caitlin John LLC acquired a new stake in shares of AbbVie during the third quarter worth about $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $232.43 on Friday. The firm has a 50 day moving average of $224.89 and a two-hundred day moving average of $203.90. The stock has a market capitalization of $410.79 billion, a PE ratio of 110.68, a P/E/G ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie has a 52 week low of $163.81 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the firm earned $3.00 earnings per share. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts predict that AbbVie will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is currently 524.24%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.